EYEN - Eyenovia Inc Stock Price, Fair Value and News

0.53USD-0.06 (-10.17%)Market Closed

Market Summary

USD0.53-0.06

Market Closed

-10.17%

EYEN Alerts

1 major insider buys recently.

EYEN Stock Price

View Fullscreen

EYEN RSI Chart

EYEN Valuation

Market Cap

25.1M

Price/Earnings (Trailing)

-0.92

Price/Sales (Trailing)

6.6K

Price/Free Cashflow

-0.94

EYEN Price/Sales (Trailing)

EYEN Profitability

Return on Equity

-302.93%

Return on Assets

-94.72%

Free Cashflow Yield

-106.25%

EYEN Fundamentals

EYEN Revenue

Revenue (TTM)

3.8K

EYEN Earnings

Earnings (TTM)

-27.3M

Earnings Growth (Yr)

-30.11%

Earnings Growth (Qtr)

-8.56%

Breaking Down EYEN Revenue

Last 7 days

-40.4%

Last 30 days

-68.8%

Last 90 days

-69.4%

Trailing 12 Months

-87.8%

How does EYEN drawdown profile look like?

EYEN Financial Health

Current Ratio

2.17

EYEN Investor Care

Shares Dilution (1Y)

22.18%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	7.0M	3.8K
2021	5.0M	8.0M	11.0M	14.0M
2020	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eyenovia Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	grant stuart m.	bought	98,000	0.98	100,000	-
Mar 19, 2024	grant stuart m.	bought	61,500	1.23	50,000	-
Mar 08, 2024	grant stuart m.	bought	16,911	1.578	10,717	-
Dec 04, 2023	rowe michael m	bought	6,650	1.36	4,890	chief executive officer
Nov 14, 2023	geltzeiler michael s	acquired	-	-	19,814	-
Sep 29, 2023	strahlman ellen r	bought	8,097	1.68	4,820	-
Sep 19, 2023	rowe michael m	bought	2,324	1.66	1,400	chief executive officer
Sep 15, 2023	rowe michael m	bought	1,989	1.75	1,137	chief executive officer
Aug 17, 2023	grant stuart m.	bought	56,100	1.87	30,000	-
Aug 16, 2023	grant stuart m.	bought	85,815	1.907	45,000	-

Which funds bought or sold EYEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 14, 2024	Leo Wealth, LLC	new	-	25,457	25,457	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.51	702,897	2,973,520	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-87.86	-508,777	91,270	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	6,181	31,104	-%
Feb 26, 2024	Virtu Financial LLC	new	-	26,000	26,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	190,066	190,066	-%
Feb 15, 2024	Farther Finance Advisors, LLC	new	-	181	181	-%
Feb 15, 2024	BARCLAYS PLC	added	663	77,000	86,000	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	1,417	7,016	-%

Are Funds Buying or Selling EYEN?

Are funds buying EYEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EYEN

No. of Funds

EYEN Alerts

1 major insider buys recently.

Unveiling Eyenovia Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.70%	4,378,000	SC 13G
Feb 13, 2023	eshelman fredric n	4.7%	1,708,548	SC 13D/A
Jan 24, 2023	ianchulev tsontcho	6.3%	2,257,422	SC 13D/A
Feb 08, 2022	grant stuart m.	18.75%	5,452,554	SC 13D/A
Dec 27, 2021	grant stuart m.	18.47%	5,416,524	SC 13D/A
Aug 24, 2021	yoshida shuhei	6.8%	1,751,900	SC 13D/A
Jun 10, 2021	grant stuart m.	18.59%	4,992,870	SC 13D/A
Nov 25, 2020	ianchulev tsontcho	7.2%	1,837,611	SC 13D/A
Nov 13, 2020	grant stuart m.	19%	4,897,178	SC 13D/A
Aug 28, 2020	ianchulev tsontcho	8.9%	2,280,739	SC 13D/A

Recent SEC filings of Eyenovia Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	424B5	Prospectus Filed
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Mar 28, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 11, 2024	4	Insider Trading
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Eyenovia Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.2B	6.8B	-1.24%	-34.47%	-8.53	5.87	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.7B	1.8B	0.05%	-28.38%	-42.48	10.23	76.23%	61.08%
BMRN	17.4B	2.4B	8.82%	-6.19%	103.82	7.19	15.42%	18.43%
INCY	12.1B	3.7B	-8.57%	-28.49%	20.24	3.27	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.73%	-34.59%	-11.81	15.74	425.83%	18.94%
BBIO	4.7B	-	-4.69%	71.46%	-7.23	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-0.99%	6.40%	-13.71	12.12	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.54%	-18.95%	-10.32	12.72	-1.03%	-92.09%
ACAD	2.8B	726.4M	-12.42%	-7.51%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-15.36%	25.1	4.5	85.90%	-14.05%
NVAX	599.0M	983.7M	-18.48%	-55.04%	-1.1	0.61	-50.36%	17.16%
CRBP	428.3M	881.7K	-13.30%	407.71%	-9.6	466.16	-77.61%	-5.33%
INO	257.8M	4.9M	-1.96%	-2.22%	-1.91	52.97	-54.97%	51.72%
IBIO	7.2M	2.1M	77.59%	88.99%	-0.26	2.14	-13.45%	66.37%

Eyenovia Inc News

Latest updates

Eyenovia Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-	-	-	10,000	-	2,000	2,000	-
Cost Of Revenue	116.1%	3.00	1.00	-	-	800	800	-
Gross Profit	-	-	-	10,000	-	1,200	1,200	-
Operating Expenses	14.5%	7,467	6,520	6,947	5,925	5,982	6,567	5,407
S&GA Expenses	-100.0%	-	2,942	3,655	2,373	2,297	2,244	1,957
R&D Expenses	13.6%	4,065	3,578	3,292	3,552	3,685	4,323	3,450
Interest Expenses	0.2%	681	679	185	119	78.00	5.00	2.00
Net Income	-8.6%	-7,967	-7,338	2,983	-5,568	-4,841	-5,351	-4,206
Net Income Margin	-198204.8%	-7.20	-3.63*	-0.91*	-1.82*	-2.44*	-3.93*	-9.88*
Free Cashflow	-1.1%	-6,467	-6,394	-12,735	1,186	-5,632	-4,918	5,394

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.5%	29.00	35.00	29.00	29.00	31.00	31.00	36.00	40.00	32.00	25.00	31.00	29.00	34.00	26.00	11.00	15.00	15.00	19.00	10.00	15.00	20.00
Current Assets	-22.0%	21.00	27.00	23.00	25.00	28.00	29.00	26.00	30.00	22.00	23.00	29.00	28.00	33.00	25.00	11.00	15.00	14.00	19.00	10.00	15.00	20.00
Cash Equivalents	-28.3%	15.00	21.00	17.00	18.00	23.00	17.00	22.00	27.00	27.00	14.00	27.00	25.00	28.00	23.00	10.00	14.00	14.00	18.00	9.00	14.00	20.00
Inventory	118.3%	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.4%	3.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	3.6%	20.00	19.00	19.00	13.00	14.00	11.00	12.00	10.00	11.00	21.00	22.00	17.00	19.00	7.00	3.00	3.00	3.00	2.00	2.00	3.00	3.00
Current Liabilities	45.5%	10.00	7.00	4.00	5.00	5.00	11.00	12.00	10.00	11.00	21.00	15.00	16.00	18.00	7.00	3.00	3.00	3.00	2.00	2.00	3.00	3.00
Shareholder's Equity	-43.0%	9.00	16.00	11.00	16.00	17.00	20.00	24.00	30.00	20.00	4.00	9.00	12.00	15.00	19.00	8.00	12.00	12.00	16.00	8.00	12.00	17.00
Retained Earnings	-5.8%	-145	-137	-130	-123	-118	-112	-104	-97.60	-90.22	-93.20	-87.63	-82.79	-77.44	-73.23	-68.14	-63.12	-57.67	-52.43	-47.78	-42.45	-36.51
Additional Paid-In Capital	0.8%	154	153	141	140	135	132	128	127	111	97.00	97.00	95.00	93.00	92.00	76.00	75.00	69.00	69.00	55.00	55.00	53.00
Shares Outstanding	6.2%	46.00	43.00	38.00	38.00	37.00	35.00	34.00	30.00	28.00	26.00	26.00	25.00	25.00	20.00	-	-	-	-	-	-	-
Float	-	-	-	88.00	-	-	-	53.00	-	-	-	113	-	-	-	32.00	-	-	-	31.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-8.7%	-6,322	-5,814	-4,741	-6,958	-5,399	-6,800	-4,715	-8,184	-12,674	1,703	-5,329	-4,573	5,453	-1,936	-3,998	-5,917	-4,020	-3,858	-5,143	-5,896	-4,105
Share Based Compensation	-6.6%	572	613	494	819	891	929	1,037	909	814	777	637	657	656	610	633	584	578	477	424	1,033	500
Cashflow From Investing	91.5%	-145	-1,703	-1,284	-838	-311	-163	-191	-207	-453	-517	-303	-344	-59.21	-69.80	-38.31	-93.93	-123	-43.48	-	-	-27.91
Cashflow From Financing	-94.3%	614	10,778	5,001	3,400	3,307	2,872	-318	15,646	12,291	-188	7,903	1,453	97.00	14,685	567	5,515	-	12,959	68.00	484	2,818

EYEN Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating Income
Revenue	$ 3,787
Cost of revenue	(3,787)
Operating Expenses:
Research and development	12,975,832	$ 13,378,680
General and administrative	12,430,614	13,532,835
Total Operating Expenses	25,406,446	26,911,515
Loss From Operations	(25,406,446)	(26,911,515)
Other (Expense) Income:
Other (expense) income , net	(176,411)	197,090
Interest expense	(2,371,851)	(1,380,058)
Interest income	693,612	83,326
Total Other Expense	(1,854,650)	(1,099,642)
Net Loss	$ (27,261,096)	$ (28,011,157)
Net Loss Per Share
Net Loss Per Share - Basic	$ (0.66)	$ (0.83)
Net Loss Per Share - Diluted	$ (0.66)	$ (0.83)
Weighted Average Number of Common Shares Outstanding
Shares Outstanding - Basic	41,032,970	33,649,747
Shares Outstanding - Diluted	41,032,970	33,649,747

EYEN Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 14,849,057	$ 22,863,520
Inventories	109,798
Deferred clinical supply costs	4,256,793	2,284,931
License fee and expense reimbursements receivable	123,833	1,183,786
Security deposits, current	1,506	119,550
Prepaid expenses and other current assets	1,365,731	1,190,719
Total Current Assets	20,706,718	27,642,506
Property and equipment, net	3,374,384	1,295,115
Security deposits, non-current	197,168	80,874
Intangible assets	2,122,945
Operating lease right-of-use asset	1,666,718	1,291,592
Equipment deposits	711,441	726,326
Total Assets	28,779,374	31,036,413
Current Liabilities:
Accounts payable	1,753,172	1,428,283
Accrued compensation	1,658,613	1,747,191
Accrued expenses and other current liabilities	287,928	503,076
Operating lease liabilities - current portion	501,250	484,882
Notes payable - current portion, net of debt discount of $503,914 and $33,885 as of December 31, 2023 and 2022, respectively	5,329,419	174,448
Convertible notes payable - current portion, net of debt discount of $0 and $33,885 as of December 31, 2023 and 2022, respectively		174,448
Total Current Liabilities	9,530,382	4,512,328
Operating lease liabilities - non-current portion	1,292,667	907,644
Notes payable - non-current portion, net of debt discount of $448,367 and $813,229 as of December 31, 2023 and 2022, respectively	4,355,800	4,190,938
Convertible notes payable - non-current portion, net of debt discount of $398,569 and $813,229 as of December 31, 2023 and 2022, respectively	4,601,431	4,190,938
Total Liabilities	19,780,280	13,801,848
Commitments and contingencies (Note 9)
Stockholders' Equity:
Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.0001 par value, 90,000,000 shares authorized; 45,553,026 and 36,668,980 shares issued and outstanding as of December 31, 2023 and 2022, respectively	4,555	3,667
Additional paid-in capital	154,486,098	135,461,361
Accumulated deficit	(145,491,559)	(118,230,463)
Total Stockholders' Equity	8,999,094	17,234,565
Total Liabilities and Stockholders' Equity	$ 28,779,374	$ 31,036,413

About Eyenovia Inc

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO	Mr. Michael M. Rowe
WEBSITE	eyenovia.com
INDUSTRY	Biotechnology
EMPLOYEES	41

Eyenovia Inc Frequently Asked Questions

What is the ticker symbol for Eyenovia Inc? What does EYEN stand for in stocks?

EYEN is the stock ticker symbol of Eyenovia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eyenovia Inc (EYEN)?

As of Fri Apr 12 2024, market cap of Eyenovia Inc is 25.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYEN stock?

You can check EYEN's fair value in chart for subscribers.

What is the fair value of EYEN stock?

You can check EYEN's fair value in chart for subscribers. The fair value of Eyenovia Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eyenovia Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eyenovia Inc a good stock to buy?

The fair value guage provides a quick view whether EYEN is over valued or under valued. Whether Eyenovia Inc is cheap or expensive depends on the assumptions which impact Eyenovia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYEN.

What is Eyenovia Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, EYEN's PE ratio (Price to Earnings) is -0.92 and Price to Sales (PS) ratio is 6.63 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYEN PE ratio will change depending on the future growth rate expectations of investors.